

## 參考文獻

1. American Cancer Society. Retrieved October 2, 2003 from the World Wide Web: <http://www.cancer.org>
2. 中華民國行政院衛生署 Retrieved 2004 from the World Wide Web: <http://www.doh.gov.tw/statistic/index.htm>
3. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer--epidemiology, risk factors and genetics. *BMJ* 321:624-8, 2000
4. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. *Cancer Res.* 59:1752s-1756s, 1999
5. Nathanson KL, Wooster R, Weber BL, Nathanson KN. Breast cancer genetics: what we know and what we need. *Nat Med.* 7:552-6, 2001
6. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. *Science.* 286:1162-6, 1999
7. Ko LJ, Prives C. p53: puzzle and paradigm. *Genes Dev.* 10:1054-72, 1996
8. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene

- and prognosis in breast cancer: a meta-analysis. *Br J Cancer*. 80:1968-73, 1999
9. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*. 250:1233-8, 1990
  10. Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. *Oncogene*. 18:2451-9, 1999
  11. Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. *J Natl Cancer Inst*. 91:469-73, 1999
  12. Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. *J Natl Cancer Inst*. 93:700-4, 2001
  13. de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind'homme B,

- Martin E, Sastre-Garau X, Magdelenat H, Fourquet A, Soussi T. p53 mutation as a genetic trait of typical medullary breast carcinoma. *J Natl Cancer Inst.* 91:641-3, 1999
14. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. *J Biol Chem.* 272:18779-89, 1997
  15. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. *Diabetes.* 46:1230-4, 1997
  16. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. *Mol Cell.* 1:465-70, 1998
  17. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor

- inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. *Proc Natl Acad Sci U S A.* 95:8806-11, 1998
18. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. *Nat Med.* 4:1058-61, 1998
  19. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. *Ann N Y Acad Sci.* 997:199-208, 2003
  20. Kumle M, Alsaker E, Lund E. Use of oral contraceptives and risk of cancer, a cohort study. *Tidsskr Nor Laegeforen.* 123:1653-6, 2003
  21. Dixon JM. Hormone replacement therapy and the breast. *Surg Oncol.* 12:251-63, 2003
  22. Diamanti-Kandarakis E. Hormone replacement therapy and risk of malignancy. *Curr Opin Obstet Gynecol.* 16:73-8. 2004
  23. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *J Clin Oncol.* 20:1128-43, 2002
  24. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. *J Natl Cancer Inst.*

- 58:525-47, 1977
25. Poschl G, Seitz HK. Alcohol and cancer. *Alcohol Alcohol.* 39:155-65, 2004
  26. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. *J Med.* 33:73-86, 2002
  27. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. *J Clin Oncol.* 21:1961-6, 2003
  28. Key TJ, Allen NE, Spencer EA, Travis RC. Nutrition and breast cancer. *Breast.* 12:412-6, 2003
  29. Coyle YM. The effect of environment on breast cancer risk. *Breast Cancer Res Treat.* 84:273-88, 2004
  30. Frazier AL, Li L, Cho E, Willett WC, Colditz GA. Adolescent diet and risk of breast cancer. *Cancer Causes Control.* 15:73-82. 2004
  31. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. *Br J Cancer.* 89:1672-85, 2003
  32. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. *Diabetes.*

53:S43-50, 2004

33. Yamamura T. Apolipoprotein E *Nippon Rinsho*. 52:3124-32, 1994
34. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. *Nature* 405:421-4, 2000
35. Escher P, Wahli W. Peroxisome proliferators-activated receptors: insight into multiple cellular functions. *Mutat Res* 448:121-38, 2000
36. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. *Biochemistry* 32:5598-604, 1993
37. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. *Biochim Biophys Acta*. 1302:93-109, 1996
38. Vanden Heuvel JP. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. *Toxicol Sci*. 47:1-8, 1999
39. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function. *Ann N Y Acad Sci*. 804:252-65, 1996

40. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM.  
Convergence of 9-cis retinoic acid and peroxisome proliferators  
signaling pathways through heterodimer formation of their receptors.  
*Nature* 358:771-4, 1992
41. Glass CK. Some new twists in the regulation of gene expression by  
thyroid hormone and retinoic acid receptors. *J Endocrinol.*  
150:349-57, 1996
42. Issemann I, Green S. Activation of a member of the steroid hormone  
receptor superfamily by peroxisome proliferators. *Nature* 347:645-50,  
1990
43. Berger J, Moller DE. The mechanisms of action of PPARs. *Annu Rev*  
*Med.* 53:409-35, 2002
44. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a  
chimera of the clofibric acid-activated receptor and the  
glucocorticoid receptor. *Proc Natl Acad Sci U S A.* 89:4653-7, 1992
45. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G,  
Brown M, Lazar MA. Differential activation of peroxisome  
proliferator-activated receptors by eicosanoids. *J Biol Chem.*  
270:23975-83, 1995

46. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. *Mol Cell.* 3:397-403, 1999
47. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. *Cell.* 93:229-40, 1998
48. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. *Cell.* 83:803-12, 1995
49. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. *Cell.* 83:813-9, 1995
50. Braissant O, Fougère F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferators-activated receptors (PPARs) : tissue distribution of PPAR- $\alpha$ , - $\beta$ , and - $\gamma$  in the adult rat. *Endocrinology* 137:354-66, 1996
51. Braissant O, Wahli W. Differential expression of peroxisome



- proliferator-activated PPAR- $\alpha$ , - $\beta$ , and - $\gamma$  during rat embryonic development. *Endocrinology* 139:2748-54, 1998
52. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptors in humans. *Diabetes* 46:1319-27, 1997
53. Martin G, Schoonjans K, Lefebvre AM, et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR $\alpha$  and PPAR $\gamma$  activators. *J. Biol. Chem.* 272:28210-7, 1997
54. Motojima K, Passilly P, Peters JM, et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. *J. Biol. Chem.* 273:16710-4, 1998
55. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the alpha isoform of the peroxisome proliferators-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. *Mol Cell Biol*

15:3012-22, 1995

56. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferators-activated receptors, orphans with ligands and functions. *Curr Opin Lipidol* 8:159-66, 1997
57. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. *Curr Opin Lipidol* 10:151-9, 1999
58. Gonzalez FJ. The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis. *Mol Cell Endocrinol.* 193:71-9, 2002
59. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. *Carcinogenesis.* 18:2029-33, 1997
60. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. *J Natl Cancer Inst.* 90:1702-9, 1998
61. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. *J Mol*

*Endocrinol.* 22:1-8, 1999

62. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. *Curr Mol Med.* 3:561-72, 2003
63. Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ, Liu KL, Fischer SM, Belury MA. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. *Mol Carcinog.* 29:134-42, 2000
64. Roberts-Thomson SJ, Snyderwine EG. Characterization of peroxisome proliferators-activated receptor alpha in normal rat mammary gland and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets. *Toxicol Lett.* 118:79-86, 2000
65. Huin C, Schohn H, Hatier R, Bentejac M, Antunes L, Plenat F, Bugaut M, Dauca M. Expression of peroxisome proliferators-activated receptors alpha and gamma in differentiating human colon carcinoma Caco-2 cells. *Biol Cell.* 94:15-27, 2002
66. Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN. Peroxisome proliferator-activated receptor alpha is an

- androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. *Clin Cancer Res.* 6:3241-8, 2000
67. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. *Mol Carcinog.* 34:165-71, 2002
68. Hagberg JM, Wilund KR, Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. *Physiol Genomics.* 4:101-108. 2000
69. Lehrer S. Possible relationship of the apolipoprotein E (ApoE) epsilon4 allele to prostate cancer. *Br J Cancer.* 78:1398, 1998
70. Wessel N, Liestol K, Maehlen J, Brorson SH. The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population. *Br J Cancer.* 85:1418, 2001
71. Venanzoni MC, Giunta S, Muraro GB, Storari L, Crescini C, Mazzucchelli R, Montironi R, Seth A. Apolipoprotein E expression in localized prostate cancers. *Int J Oncol.* 22:779-86. 2003
72. Shinomiya S, Sasaki J, Kiyohara C, Tsuji E, Inoue H, Marugame T, Handa K, Hayabuchi H, Hamada H, Eguchi H, Fukushima Y, Kono S.

- Apolipoprotein E genotype, serum lipids, and colorectal adenomas in Japanese men. *Cancer Lett.* 164:33-40, 2001
73. Watson MA, Gay L, Stebbings WS, Speakman CT, Bingham SA, Loktionov A. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. *Clin Sci (Lond)*. 104:537-45, 2003
74. Lichtor T. Gene expression of apolipoprotein E in human brain tumors. *Neurosci Lett.* 138:287-90, 1992
75. Zozulia IuA, Shostak EA, Garifulin OM, Rozumenko VD, Khomenko AV, Dmitrenko VV, Kavsan VM. Role gene expression changes in development of human brain gliomas. *Zh Vopr Neurokhir Im N N Burdenko.* (2):43-9; discussion 49-50, 2002
76. Tanne JH. Apo E4 gene linked to breast cancer. *BMJ.* 319:662, 1999
77. Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Bowman ED, Schisterman EF, Vena JE, Shields PG. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. *Mol Carcinog.* 27:2-9, 2000
78. Zunarelli E, Nicoll JA, Migaldi M, Trentini GP. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell

- proliferation indices and clinical outcome. *Breast Cancer Res Treat.* 63:193-8, 2000
79. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. *Am J Epidemiol.* 155:487-95, 2002
80. Qi X, Pramanik R, Wang J, Schultz RM, Maitra RK, Han J, DeLuca HF, Chen G. The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition. *J Biol Chem.* 277:25884-92, 2002
81. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. *Anal Biochem.* 150:76-85, 1985
82. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. *J Biol Chem.* 19;271:1764-9, 1996
83. National Center for Biotechnology Information Retrieved 2004 from

the World Wide Web: <http://www.ncbi.nlm.nih.gov/BLAST/>

84. Missouri Retrieved 2004 from the World Wide Web:  
<http://www.biotech.missouri.edu/mbp/exchange/tips/index.html>
85. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. *Diabetologia*. 43:673-80, 2000
86. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. *Arterioscler Thromb Vasc Biol*. 22:805-10, 2002
87. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. *J Med Genet*. 39:189-91, 2002
88. Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during

- endotoxemia. *Infect Immun.* 67:3488-93, 1999
89. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J.  
Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. *J Biol Chem.* 272:28210-7. 1997
90. Karam WG, Ghanayem BI. Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures. *Carcinogenesis.* 18:2077-83. 1997
91. Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. *Atherosclerosis.* 52:339-46. 1984
92. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CA. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. *J Biol Chem.* 274:10505-10, 1999